Company Overview of ImQuest Pharmaceuticals, Inc
ImQuest Pharmaceuticals, Inc. develops drugs for the treatment of infectious diseases, cancer, and inflammation. The company focuses on various drug development programs, such as therapies for the treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), and cancer, as well as on topical microbicides for the prevention of transmission of HIV and other sexually transmitted infections. It develops a vaginal gel for the prevention of HIV transmission to women. The company was founded in 2005 and is based in Frederick, Maryland.
7340 Executive Way
Frederick, MD 21704
Founded in 2005
Key Executives for ImQuest Pharmaceuticals, Inc
President and Chief Scientific Officer
Director of Biological Sciences and Director
Compensation as of Fiscal Year 2015.
ImQuest Pharmaceuticals, Inc Key Developments
ImQuest Pharmaceuticals Receives FDA Approval to Initiate Clinical Trials of Vaginal Gel for the Prevention of HIV Transmission to Women
Jul 16 14
ImQuest Pharmaceuticals was recently notified by the US Food and Drug Administration of the approval of its Investigational New Drug (IND) application to study the safety in Phase 1 clinical trials of its vaginal gel containing the nonnucleoside reverse transcriptase HIV Inhibitor IQP-0528. Preclinical studies have shown that IQP-0528 is highly effective against virus strains found throughout the world, prevents HIV transmission in cultured cells, causes sterilization of cultures infected with HIV, and acts in concert with other approved HIV drugs to inhibit the virus. The IQP-0528 vaginal gel is being developed with the goal of preventing the sexual transmission of HIV to women throughout the world. ImQuest plans to evaluate the safety of the IQP-0528 vaginal gel in a Phase I clinical trial at medical centers in the United States and expects to begin recruiting women for the trial by the end of the year. This marks the company's first product to receive FDA approval for clinical trials. ImQuest Pharmaceuticals developed the HIV inhibitor in partnership with Samjin Pharmaceutical Co. Ltd. of Seoul Korea. Preclinical testing was conducted by ImQuest BioSciences of Frederick, Maryland using the company's newly launched ImQuestSUCCESS(TM) platform, which enables the rapid identification of drug candidates with a high probability of clinical success early in the discovery and development process. Development of ImQuest's prevention products has been supported in part by the National Institutes of Health and the International Partnership for Microbicides, which is funded by The Bill and Melinda Gates Foundation and The United States Agency for International Development (USAID). The company plans to submit a second IND to the FDA for approval to test IQP-0528 in a DuoGel(TM) formulation for protection of both vaginal and rectal virus transmission to men and women early next year -- a product which will represent a major advancement for microbicide products in the pharmaceutical industry.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries